Phase 1b/2 Study of Futibatinib in Combination With Binimetinib in Patients With Advanced KRAS Mutant Cancer

Summary

Phase 1b/2 study to evaluate the FGFRi futibatinib in combination with the MEKi binimetinib in patients with advanced KRASmt tumors.

Timeline

Start

2021-09-20

Primary completion

2023-06-11

Completion

2023-09-21

Publications

• Rodon J, O'Neil B, Lim C, Ammakkanavar NR, Torrado C, Matsuoka K, Hirai H, Miura A, Anderson B, Jin L, Hangai N, Long A, Wacheck V, Rosen L. Preclinical and clinical evaluation of futibatinib in combination with binimetinib in patients with advanced cancer. Invest New Drugs. 2026 May 18. doi: 10.1007/s10637-026-01618-y. Online ahead of print.

Drugs

Indications